ã¯ã¯ãã³ãããæææº
ãã€ã¢ãã®ç§ç«åŠæ ¡åŠé·Leila Centnerãããåœæ ¡ã§ã¯ã³ããã¯ã¯ãã³ãæ¥çš®ããã¹ã¿ããã¯éçšããŸãããæ¥çš®ããŠããŸã£ãã¹ã¿ããã«ã€ããŠã¯ãçåŸãããªãã¹ãé¢ããŠããããŸããããã¯ãâã³ããã¯ã¯ãã³ãæ¥çš®ããäººãæªæ¥çš®è
ã«æªåœ±é¿ãåãŒããŠããâãšã®ã¬ããŒããåããŠã®å¯Ÿå¿ã§ãã
âã¯ã¯ãã³æ¥çš®è
ã®äœå
ããã¯äœããã®æå®³ç©è³ªãæåºãããŠãããããã女æ§ã®çæ®ç³»ãåäŸã®æ£åžžçºéã«æªåœ±é¿ãäžããæããããâãšã®ããšã§ãã
å®éãæã
ã®èº«è¿ã«ããã¯ã¯ãã³æ¥çš®è
ãšäžç·ã«éãããããã§æçµåšæã®ä¹±ããæ¥ãã人ããå°ãªããšãäžäººããŸãã
åŸã£ãŠåœæ ¡ã§ã¯ãçåŸãå®ãããã«ãã³ããã¯ã¯ãã³ãæ¥çš®ããæå¡ãçåŸã«è¿ã¥ãããšãçµæ¥çŠæ¢ããŸãã
è±æã§ããããã€ãé©åã ãšæãããã®æ ¡é·ããã¹ã³ãããæ»æãããŸãã£ãŠããã©ãé 匵ã£ãŠã»ãããªã
ãã¯ã¯ãã³æ¥çš®è
ãåšå²ã«ç
æ°ããŸãæ£ããã
ããã¯é°è¬è«ã§ãæšæž¬ã§ãäœã§ããªããŠããã¡ã€ã¶ãŒç€Ÿã®æ²»éšææžã«ã¯ã£ããæžããŠããã
shedding(ç
åäœã®å¯Ÿå€ãžã®æåº)ã®ç ç©¶
ãåžå
¥ã«ããä»å
¥ãŸãã¯ç®èæ¥è§Šã«ããä»å
¥ã§æé²ããåŸã«åŠåš ãã女æ§ã®äŸã
ãåžå
¥ã«ããä»å
¥ãŸãã¯ç®èæ¥è§Šã«ããä»å
¥ã§æé²ããç·æ§ããããŒãããŒã®å¥³æ§(æåµæã®ååŸã®ã¿ã€ãã³ã°ã§)ãç
åäœã«æé²ãããäŸã
https://media.tghn.org/medialibrary/2020/11/C4591001_Clinical_Protocol_Nov2020_Pfizer_BioNTech.pdf#page67
ã¯ã¯ãã³ãææçãé²ãã©ãããããããææçã®èªå ã§ã¯ãªããããšããäºäŸã¯ãããã§ããããããšãã°ããããã®ã
ãã€ã³ãã«ã¯ã¯ãã³ãå
šå¡æã£ãŠããã®ã«é壿æ(2019幎1æ)ã
å¯é¢é·ãäºé²æ¥çš®ã®å¹æãä¹ããã®ã§ã¯ãªãããšæããããåŸãªãã
ããã广ããªããã®ã§ã¯ãªããåå ãªãã ããããå æžæ°ä»ããŸããããã
ãããã¯ã¯ãã³æã£ãŠã€ã³ãã«ã«ãããçšåºŠã§æžãã°ãŸã ããã
ã³ããã¯ã¯ãã³ã¯ãæ®éã«æ»ã«ãŸãããã
è±åœæ¿åºãã³ããç¬¬ïŒæ³¢ã«ãããã¯ã¯ãã³ãïŒåæ¥çš®ãã人ã®ãã¡60ïœ70ïŒ ã®äººãæ»äº¡ãããããããã¯å ¥é¢ããããšã«ãªãã ããã
ãVAERSã«ãããšãã³ããã¯ã¯ãã³ãæ¥çš®ãã18ïœ29æ³ã®ç±³åœäººã¯ãã€ã³ãã«ã¯ã¯ãã³ãæ¥çš®ããå Žåã«æ¯ã¹ãŠã11å以äžå
¥é¢ããå¯èœæ§ãé«ãã100åä»¥äžæ»äº¡ããå¯èœæ§ãé«ãã
äžæ¹ãæè¿ã®æ¥æ¬ã®ãã¥ãŒã¹ããã
ãã¯ã¯ãã³ã®å¯åå¿ã§ä»äºã«åºãããªããªãã°ã1æ¥4ååæ¯çµŠã
ã€ã³ãã«ã¯ã¯ãã³ã®åŸéºçã§ä»äºäŒãã ããã£ãŠããããªäŒæ¥è£åãåºãªãããïŒãŠããšã¯ãåœã¯ã³ããã¯ã¯ãã³ã®å±éºæ§ãèªãããã£ãŠããšã§ããã§ããïŒ(ç¬)
ãã³ããã¯ã¯ãã³æ¥çš®ãèªè¡éãèšçœ®ãšéå¶ã
ãããªãã ãããªããšæã£ãŠãããããã§ã«ã¢ã¡ãªã«ã§ã¯ã³ããã¯ã¯ãã³ã®é
éã«è»ãé¢äžããŠãããããæ¥æ¬ã§ãåæ§ã®åããããã ãããªãšã
èªè¡éãåå¡ããšèããŠããæãããšæããªããšãããªãããä»ã®ãšããã¯ã¯ãã³äŒå Žã®èšå¶ãšéå¶ã ãã圌ãã®ä»»åã ãã©ããã®ãã¡åå®¶åºãèšªåæ¥çš®ããªããŠããšã«ãªããããªãã
ããããããã£ãšã¯ã¯ãã³ã®æã¡æãå¢ããïŒããšã®ãéããããããããæ¥æ¬æ¿åºãå¿
æ»ã®ããã§ãã
æ¯ç§å»åž«ãè¬å€åž«ãææ¥æåœå£«ãã¯ã¯ãã³ãæãŠãããã«ããŠããããšã
ãããããããæ¯å»è
ãããšææ¥æåœå£«ã¯ãšããããè¬å€åž«ãŸã§åå¡ã£ãŠãšãããããããè¬å€åž«ã¯ãå»çåŸäºè
ã§ã¯ãããã©ãæ£è
ã«éåºããšãããã£ãããšãªããšæããã ãã©(ç¬)
ãšæã£ãŠããããã£ãšããããã¥ãŒã¹ãé£ã³èŸŒãã§ããã
è¬å€åž«ã©ããããå»åŠéšçãçè·åŠéšçãã¯ã¯ãã³ãæãŠãããã«ãªããã£ãŠããã
ãããåŠçã«æãããã£ãŠãã»ããŸããã®åŠåŸåå¡ãã(ç¬)
ãããŸã§ã®ç·æ¥äºæ
ãªã®ïŒã£ãŠããããã³ãã¯éæ®ã§ããšã«ãããããããããã¯æãæŒåºããŠãã人å¡ãé§ãéããŠãŸã§çããã«ã¯ã¯ãã³ãå±ããããã ïŒãã£ãŠããé°å²æ°äœãã ãšæãã®ãã
ã¿ãªãããã©ãããå·éã«ã(ç¬)
倧æã¡ãã£ã¢ã¯ãã€ã³ãã§ææççºããšã人ã ã®ã³ããäžå®ãç œãããããã ãã©ããã
3幎åã®åçãæµçšãšãããã£ã±ãä»äºãé(ç¬)
ã¬ã¹æŒãäºæ
ã§æ»ãã 人ã®åçããã³ããæ»ãšããŠæµçšã
ããããæé ã¯æ
£ãã£ãã ãããããããïŒãã£ãŠçªã£èŸŒãã®ãç²ãã(ç¬)
ã€ã³ãåšäœã®å¥³æ§ãã誰äžäººæ»ãã§ãªãããšæŽé²ããŠãã
å人ãåç»é
ä¿¡ã§ããæä»£ã ãïŒåœå±ããã³ãããã¯ãæŒåºãããã«ãããããåºãã«æ±ºãŸã£ãŠãããã¹ã³ãã«ã¯ããããããšãããã£ãŠèšã£ãŠãããã(ç¬)
以äžãã³ããã¯ã¯ãã³ã®è¢«å®³ãæããŠããã
ããã®ãå¿èçºäœãèµ·ããŸãããããšããšå¿èã¯ãŸã£ããæ£åžžã§å¥åº·ã§ãããã§ãå
é±ãã¡ã€ã¶ãŒè£œã¯ã¯ãã³ãåãããã§ãããã®ã¯ã¯ãã³ã®ããã§å¿èã®å䜵çãèµ·ãããšããå ±åããããŸããã
äœãä»ã«åå ãããå¯èœæ§ã¯é€å€ãããŸããããã®ã¯ã¯ãã³ã®ããã§èµ·ãã£ããšãããããèããããŸããã
ããã³ã·ã«ããã¢ã®å¥³æ§ããã¡ã€ã¶ãŒã¯ã¯ãã³ååæ¥çš®åŸã«éº»çºã
ãããã·ã¥ãã«ã®å¥³æ§ããã¡ã€ã¶ãŒã¯ã¯ãã³æ¥çš®åŸã«éº»çºã
æ»äº¡çäŸã¯æ²æšã ãã©ããªããšããããæ»äººã«å£ãªããã§ã亡ããªã£ãäººã®æ°æã¡ãèãããšã¯ã§ããªããã§ããé節ãªåŸéºçã§ãšã©ãŸã£ã人ã¯ãå°ãªããšãæ»ãã§ããªããããä»ã®æ°æã¡ãèªãããšãã§ããããã¯ã¯ãã³ã§æ»ãã ããšããã®ã¯ã€ã³ãã¯ãããããã©ãåãã¯ãã£ãšãéã被害ãåãã人ã®å£°ãèãã¹ãã ããããããªããšã«ãªããšã¯æããªãã£ãããæã€ã¹ããããªãã£ãããšããäœéšããã«ãã¿åºã声ã ãã«ãåããããã















